Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 16/20 | 0.88 |
| ▸ | ERBB2 | P04626 | 15/20 | 0.88 |
| ▸ | EPHA2 | P29317 | 16/20 | 0.76 |
| ▸ | EPHB4 | P54760 | 13/20 | 0.70 |
| ▸ | FLT1 | P17948 | 8/20 | 0.70 |
| ▸ | EGFR | P00533 | 2/20 | 0.69 |
| ▸ | GAK | O14976 | 1/20 | 0.69 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.69 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.69 |
| ▸ | STK10 | O94804 | 1/20 | 0.69 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.69 |
| ▸ | ABL1 | P00519 | 1/20 | 0.69 |
| ▸ | LCK | P06239 | 1/20 | 0.69 |
| ▸ | YES1 | P07947 | 1/20 | 0.69 |
| ▸ | LYN | P07948 | 1/20 | 0.69 |
| ▸ | RET | P07949 | 1/20 | 0.69 |
| ▸ | HCK | P08631 | 1/20 | 0.69 |
| ▸ | BCR | P11274 | 1/20 | 0.69 |
| ▸ | SRC | P12931 | 1/20 | 0.69 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL908466 | 0.94 | ERBB2 (1.00) | KDRERBB2EPHA2EPHB4FLT1 | |
| SCHEMBL907188 | 0.92 | ERBB2 (0.87) | KDRERBB2EPHA2EPHB4FLT1 | |
| SCHEMBL14147708 | 0.88 | KDR (0.85) | KDRERBB2EPHA2EPHB4FLT1 | |
| SCHEMBL909713 | 0.88 | ERBB2 (0.88) | KDRERBB2EPHA2EPHB4FLT1 | |
| SCHEMBL1225455 | 0.88 | ERBB2 (0.87) | KDRERBB2EPHA2EPHB4FLT1 | |
| SCHEMBL907306 | 0.87 | ERBB2 (1.00) | KDRERBB2EPHA2EPHB4FLT1 | |
| SCHEMBL906967 | 0.86 | EPHA2 (1.00) | KDRERBB2EPHA2EPHB4EGFR | |
| SCHEMBL1225900 | 0.85 | ERBB2 (1.00) | KDRERBB2EPHA2EPHB4FLT1 | |
| SCHEMBL14148143 | 0.85 | ERBB2 (0.83) | KDRERBB2EPHA2EPHB4FLT1 | |
| SCHEMBL906640 | 0.83 | ERBB2 (1.00) | KDRERBB2EPHA2EPHB4FLT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060069077-A1 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2006-03-30 | — | — | US | claimed |
| US-20240156825-A1 | USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS | FOUNTAIN THERAPEUTICS INC (US) | 2024-05-16 | — | — | US | disclosed |
| US-10266518-B2 | Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof | SYMPHONY EVOLUTION, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| US-10266518-B2 | Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof | SYMPHONY EVOLUTION, INC. (US) | 2019-04-23 | — | — | US | disclosed |
| EP-2101759-B1 | METHODS OF USING MEK INHIBITORS | EXELIXIS INC (US) | 2018-10-10 | — | — | EP | disclosed |
| US-20180118724-A1 | Receptor-Type Kinase Modulators and Methods of Use | SYMPHONY EVOLUTION, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118724-A1 | Receptor-Type Kinase Modulators and Methods of Use | SYMPHONY EVOLUTION, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118724-A1 | Receptor-Type Kinase Modulators and Methods of Use | SYMPHONY EVOLUTION, INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-9796704-B2 | Substituted quinazolines as receptor-type kinase inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-9796704-B2 | Substituted quinazolines as receptor-type kinase inhibitors | SYMPHONY EVOLUTION, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| EP-2277867-A2 | Compounds, pharmaceutical compositions thereof and their use in treating cancer | Symphony Evolution, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20100209420-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA | EXELIXIS, INC. (US) | 2010-08-19 | — | — | US | disclosed |
| US-20090318373-A1 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2009-12-24 | — | — | US | disclosed |
| US-20090318373-A1 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2009-12-24 | — | — | US | disclosed |
| US-20090318373-A1 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2009-12-24 | — | — | US | disclosed |
| US-7576074-B2 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2009-08-18 | — | — | US | disclosed |
| US-7576074-B2 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2009-08-18 | — | — | US | disclosed |
| US-7576074-B2 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2009-08-18 | — | — | US | disclosed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | disclosed |
| US-20060069077-A1 | Receptor-type kinase modulators and methods of use | KADMON CORPORATION, LLC | 2006-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060069077-A1 | Receptor-type kinase modulators and methods of use | EGFR, EPHA2, ERBB4 | KDR 17/4885ERBB2 5/4885EPHA2 2/4885 |
| US-10266518-B2 | Solid dosage formulations of substituted quinazoline receptor-type kinase modulators and methods of use thereof | EGFR, ERBB4, ERBB3 | KDR 16/4885ERBB2 6/4885EPHA2 4/4885 |
| US-20180118724-A1 | Receptor-Type Kinase Modulators and Methods of Use | EGFR, EPHA2, ERBB4 | KDR 17/4885ERBB2 5/4885EPHA2 2/4885 |
| US-20100209420-A1 | METHODS OF TREATING CANCER USING PYRIDOPYRIMIDINONE INHIBITORS OF P13K ALPHA | TP53, PHKG1, TNNI3K | KDR 2390/4885ERBB2 1137/4885EPHA2 2745/4885 |
| US-20240156825-A1 | USE OF SELECTIVE VEGFR2 AND FGFR1 INHIBITORS | FGFR1, FRS2, FGFR2 | KDR 5/4885ERBB2 46/4885EPHA2 1924/4885 |
| US-20090318373-A1 | Receptor-type kinase modulators and methods of use | EGFR, EPHA2, ERBB4 | KDR 17/4885ERBB2 5/4885EPHA2 2/4885 |
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | KDR 1023/4885ERBB2 109/4885EPHA2 977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.